THE SYSTEM OF CENTRALIZATION OF ORPHAN DRUG PURCHASES AS A GUARANTOR OF DRUG PROVISION FOR PATIENTS IN RUSSIA

Abstract

Aim. Of the article is to analyze of the system centralization of orphan drug purchases by the Federal Government Agency "Federal Center for Planning and Organization of Drug Provision for Citizens" of the Ministry of Health of the Russian Federation on drug provision (FGA "FCPODPC" of the Ministry of Health of the Russian Federation).

Materials and methods. We reviewed Russian legislation regulating the field of healthcare and drug provision, studied consumer preferences, evaluated the activities of competitors, and analyzed general trends in the field of drug circulation. The main focus was on system analysis, which allowed us to deeply understand the mechanisms and organization of drug procurement. This approach ensured a comprehensive and objective study of all processes.

Results. As part of the analysis of procurement categories by the number of international nonproprietary names (INN) and the total cost of purchased medicines, the absolute leader was identified, the presented the category "HIV in combination with hepatitis". The share of INN drugs in this category is 32.3% of the total, which correlates with their share of the total purchase price, which is 32.05%. A detailed analysis of the cost of purchases within each category made it possible to identify the most expensive and least expensive items. An expensive contract for the purchase of the drug Nusinersen was implemented as a part of the program «Circle of Good». The least expensive purchase was the drug Efavirenz, intended for the treatment of patients with HIV infection and hepatitis. «The Circle of Good» Foundation has concluded 44% of all contracts related to the medicine purchase. The Joint Stock Company «Pharmstandard» has paid the largest amount for medicines intended for the treatment of HIV infection and hepatitis. This fact reflects the amount of financial costs for the purchase of medicines for the mentioned categories of patients, and also demonstrates the effectiveness of joint procurement procedures.

Conclusion. FGA "FCPODPC" has achieved significant success in optimizing drug costs for patients with rare diseases, which demonstrates Russia's commitment to the principle of balanced drug provision. This principle presupposes decision-making based on the real capabilities of budgets and extra-budgetary sources.